Craneware (LSE:CRW), the Edinburgh-based provider of financial and operational software to US hospitals, is one of the larger and more established technology companies on London's junior market.
What the company does
Craneware develops software and data analytics that help US healthcare providers manage revenue, costs and operational performance. Its customers are mainly hospitals and health systems in the United States, where complex billing, reimbursement and regulatory rules make revenue integrity a significant challenge. The company's products address areas such as charge capture, pricing transparency, pharmacy management, including the 340B drug pricing programme, and decision support for financial and clinical leaders.
Craneware was co-founded by Keith Neilson, who has led the business as chief executive. In 2021 the company completed its largest acquisition, buying Sentry Data Systems, a US provider of pharmacy and data analytics solutions. The deal substantially increased the group's scale and data capabilities, and the combined offering has been brought together on the Trisus platform, a cloud-based suite through which customers access the company's applications and analytics.
Latest developments
Craneware's financial year ends on 30 June, and it usually publishes full-year results in the autumn. Key topics in recent reporting periods have included annual recurring revenue growth, customer retention, the adoption of Trisus products and the use of artificial intelligence within its analytics.
Financial and dividend picture
Craneware's revenue is predominantly recurring, coming from multi-year software contracts, which provides a degree of visibility. The company has a record of paying dividends, unusual for a growth-focused software business on AIM, and it has used cash generation to reduce debt taken on to fund the Sentry acquisition. Investors also watch adjusted EBITDA margins and cash conversion.
Sector and index context
Craneware (LSE:CRW) is a constituent of the FTSE AIM All Share Index, and has long been among the larger companies by market value on AIM. Healthcare technology is a notable area of the market, and Craneware's US focus means its performance reflects conditions in the American hospital sector rather than the UK economy. US hospitals have faced pressure from labour costs, reimbursement changes and policy uncertainty, which can influence software spending decisions.
Key risks
The group is heavily exposed to US healthcare policy, including any changes to the 340B programme, Medicare and Medicaid reimbursement or hospital pricing rules. Hospital budgets can come under pressure, lengthening sales cycles. Competition from larger healthcare IT companies and new AI-driven entrants is a further risk. Because the company reports in US dollars but is listed in London, currency movements can affect how results are perceived by UK investors, and data security is a critical operational concern.
What to watch next
Investors will focus on growth in annual recurring revenue, the pace of cross-selling across its customer base and progress in launching AI-enabled products on Trisus. Commentary on the US hospital spending environment and any policy developments affecting pharmacy programmes will be important. The company's full-year results, annual general meeting statement and half-year results are the key scheduled updates.
_11_16_2026_14_47_34_233787.jpg)





Please wait processing your request...